Avingtrans plc (LSE:AVG) has spent most of its life as a quietly compounding engineering group, buying niche industrial businesses, fixing them and selling them on. In 2026 that low profile is becoming harder to maintain. On 10 July the Chatteris-based company raised £21m in a placing that was more than three times oversubscribed, earmarked for a US nuclear Manufacturing expansion that management says could add £27m to £45m of annual Revenue by FY31. The shares have climbed from a 52-week low of 452p last September to a high of 740p on 27 August, according to lse.co.uk data.
The question is whether the nuclear resurgence, a growing data-centre pipeline and a medical imaging division finally reaching the market justify that re-rating, with results for the year to 31 May 2026 due on 30 September.
£21m placing funds a Michigan nuclear build-out
The most significant recent development came on 10 July 2026, when Avingtrans completed an accelerated bookbuild raising £21m gross (£19.9m net) through the issue of 3,309,000 new shares at 630p, about 9.8% of the existing share capital. Non-executive chairman Roger McDowell subscribed for roughly £0.8m, and a Blue-Chip institutional investor committed up to £11m as a cornerstone. The new shares were admitted on 14 July, taking the total in issue to 36,931,072.
The proceeds are directed to Hayward Tyler, the group's nuclear pump and motor specialist: roughly £7m for its Michigan Facility build-out, £4m for equipment, £1m for workforce expansion, £3m for Working Capital and £5m as contingency. Management expects nuclear revenue to grow from around £35m today to about £90m over five years on the basis of known customer orders, and projects that the expanded Hayward Tyler could generate £27m to £45m of additional revenue by FY31 and £9.6m to £17m of incremental EBITDA, figures it caveats as subject to assumptions. Chief executive Steve McQuillan said the outcome "reflects the strong support of both existing and new shareholders for our growth strategy."
What Avingtrans does
Avingtrans is a "buy and build" engineering group operating in highly regulated markets under a strategy it calls Pinpoint-Invest-Exit, or PIE: it acquires niche engineering businesses, invests to improve them and ultimately sells them, recycling the capital.
The larger division, Advanced Engineering Systems (AES), generated £151.5m of the group's £156.4m of revenue in the year to 31 May 2025. Its businesses include Hayward Tyler and Energy Steel in nuclear pumps, motors and reactor components, Booth Industries in high-security doors, and Maloney-Metalcraft and Ormandy Rycroft in process equipment. Customers span nuclear new build, life extension and decommissioning, infrastructure such as HS2, and increasingly data centres, with revenue split between original equipment and higher-margin aftermarket work.
Medical & Industrial Imaging (MII) houses Adaptix, a developer of low-dose 3D X-ray systems, Magnetica, which is developing compact MRI scanners, and Scientific Magnetics, a magnet maker now supplying Quantum Computing customers. MII is loss-making and at an early commercial stage.
Financial performance: steady half, stronger margins
The most recent hard figures are the interim results for the six months to 30 November 2025, published on 25 February 2026. Group revenue was essentially flat at £78.1m (H1 FY25: £79.0m), but gross Margin improved to 31.7% from 30.0%, lifting adjusted EBITDA 10.4% to £9.6m and adjusted profit before tax 27.1% to £5.7m. Statutory profit before tax rose to £5.0m from £3.8m, adjusted Diluted Earnings per Share increased to 14.6p from 12.0p, and Operating Cash Flow improved to £7.6m from £4.9m. Net Debt excluding leases was unchanged at £12.3m, and the Interim Dividend was raised to 2.0p from 1.9p.
AES revenue slipped to £75.2m from £76.8m as original-equipment sales fell 7.1%, offset by 8.0% aftermarket growth; MII revenue grew 33% to £2.9m and its EBITDA loss halved to £0.8m. For context, the year to 31 May 2025 delivered revenue of £156.4m (up 14.5%), adjusted EBITDA of £16.7m, adjusted EPS of 23.7p and a total dividend of 4.9p.
The 24 June 2026 trading update said FY26 profit is expected to be in line with market expectations, though it gave no figures. It flagged that MII revenue had been lower than anticipated because of regulatory timing delays, and that about $5.0m of a US Paycheck Protection Program Loan is to be repaid over roughly 24 months.
Catalysts: nuclear orders, data centres and imaging approvals
Nuclear is the clearest driver. Since the start of 2026 the group has reported more than £10m of nuclear orders, including a £3m reactor water clean-up pump for Iberdrola's Cofrentes plant in Spain, a $4m spares contract with Korea Hydro & Nuclear Power, a first $1.8m order from BWX Technologies and long-lead items for prototype small modular reactor pumps. Chief operating officer Austen Adams said the group was "already well advanced developing prototypes for one of the world's leading SMR companies."
Data centres are an emerging second leg, with around £4m of cumulative revenue and an identified pipeline of about £40m, while Booth Industries' HS2 awards now exceed £50m. In imaging, Adaptix's Ortho350 has secured FDA 510(k) clearance (November 2025) and CE certification (May 2026), Magnetica's US clearance is pending, and Scientific Magnetics has received more than 30 quantum computing orders. The FY26 results on 30 September should show how these threads are converting into revenue.
Risks investors should watch
The Investment case now rests heavily on a multi-year US capacity expansion whose returns depend on nuclear customers ordering on the timetable management expects. Delays to new-build and SMR programmes, which are politically and financially sensitive, would push out the payback.
MII remains a drag on profits, with an operating loss of £5.7m in FY25, and regulatory timing has already slowed revenue. Further slippage at Magnetica or slow distributor traction for Adaptix would prolong the cash burn.
Group revenue was flat in the first half, so the growth story rests on expectations for FY27 onwards rather than delivered numbers. Net debt of £12.3m, the PPP loan repayment, lumpy contract-based working capital and the 9.8% dilution from the placing all Warrant monitoring. With a Market Capitalisation of roughly £270m and a trailing price-to-earnings ratio near 39 on lse.co.uk data, the shares already discount considerable growth, and the group carries significant US dollar exposure.
Outlook
Avingtrans enters its FY26 results with a freshly funded balance sheet, a clear nuclear growth plan and a share price near a 52-week high. The 30 September announcement will show whether profit landed in line with expectations and, more importantly, how much of the nuclear and data-centre pipeline has converted into firm orders for FY27, the year management has identified as the point at which growth accelerates. An update on Magnetica's US submission and MII's path to break-even will also matter. Whether the "sleeper" label still applies after a strong twelve months is debatable, but the mix of visible orders and unproven expansion makes the next results statements unusually important.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...